InvestorsHub Logo

ombowstring

09/15/20 9:37 AM

#116673 RE: Saltz #116640

The author is not all that well-informed -

"Overall, my bull thesis remains intact and I am still keeping to my “ditch list” of CytoDyn receiving FDA approval for Leronlimab in HIV in combination with HAART, and the company begins the process of uplisting to a major exchange by the end of 2021."

Begins the process of uplisting by end of 2021??

Have no idea what he means by ditch list. Googled it, found nothing.

Black-Ops

09/15/20 9:49 AM

#116678 RE: Saltz #116640

Saltz is referring to the latest Seeking Alpha report. Interesting report on the various battles between Longs and despicable shorts. Author mixes Naval terms with Army weapons and strategies.

One of the main points this author makes is Know Your Company. Know the facts. With the facts you can spots the half, quarter, 10% truths put forward by the shorts.

I call this the Big Picture. Investing takes mental work. Investors that Avoid this work do so at their own peril.